Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CETUS BEGINNING PEG/IL-2 PHASE I CLINICALS

Executive Summary

CETUS BEGINNING PEG/IL-2 PHASE I CLINICALS, following FDA approval of the company's IND the week of April 11. "This new [polyethylene glycol/interleukin-2] product . . . has the potential to broaden the use of interleukin-2 through increased antitumor activity, reduced side effects and easier administration," Cetus noted in an April 18 press release. The dose-ranging trial will take place at the University of California, Davis Medical Center in Sacramento under the direction of Frederick Meyers, MD, and is expected to last approximately six months. Cetus said the study will include 20-30 patients with refractory metastatic cancer. Polyethylene glycol can be used to alter the surface structure of proteins, thereby changing where proteins go in the body. As a result, PEG-modified proteins can have longer half lives with less potential for immune responses. Among the advantages of the PEG/IL-2 product over the standard formulation, Cetus noted, are a less frequent dosing regimen and the potential for subcutaneous, and thus self-administration. The Phase I study will examine PEG/IL-2 given in a bolus injection once or twice a week. In studies to date with interleukin-2, the lymphokine has been administered intravenously once or twice daily. The initial PEG technology development work was performed at Rutgers University. Research Corporation Technologies, an arm of Rutgers, is the patent holder. Cetus is developing its PEG/IL-2 product under an exclusive worldwide license. Enzon, a biotech firm whose founders include members of the Rutgers research group, has also licensed the patent for the development of other PEG-modified compounds. Cetus said it has filed patent applications specifically covering the new IL-2 formulation. The biotech firm also reported that animal studies have indicated that PEG/IL-2 may have greater antitumor activity than the standard IL-2 product and be less toxic as well. Cetus has filed for regulatory approval of its Proleukin IL-2 brand in several European countries and is in Phase III clinicals in the U.S.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel